Challenges with Solubility and Bioavailability Video, Part 1 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Challenges with Solubility and Bioavailability Video, Part 1

Pharmaceutical Technology



Recorded live at the Interphex 2013 trade show, Rita Peters asks Jeffery C. Basham, vice president, business development: From your experience, do you find that the related project work for solubility/bioavailability enhancement is mostly applied for new drug development or do you see it also driving growth in projects for product lifecycle management, for example, to improve dosing schemes/regimes? Can you provide an example of either case?

Check out the rest of the interview:

Part 2

Part 3

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here